GlaxoSmithKline GSK
$50.33 −$0.08 (-0.16%)
Market closed · Nov 7, 9:10 am ET · Last extended-hours $50.33 0.00%
Open$49.07
Prev close$50.41
Day range$48.94 – $50.74
Volume3.19M
Market cap$100.88B
P/E (TTM)17.5
Dividend yield3.56%
GSK Stock News
Headlines matching GlaxoSmithKline or the GSK ticker, most recent first.
- Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
- GSK Target Started at GBP19.75 by RBC
- US Stock Market Movements | HUTCHMED (HCM.US) Surges Over 14% on Licensing Agreement with GlaxoSmithKline for Cancer Drug Positive
- GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.
- GSK Target Raised to GBP22.00 From GBP20.00 by Berenberg Positive
- J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
- J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
- J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
- TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $70
- TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70 Positive
- J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
- GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
- Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $67.1 Positive
- TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Raises Target Price to $70 Positive
- J.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)
No comments yet — be the first to weigh in on GSK.
Sign in to join the discussion.